
Thomas Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/691102/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human Cannabinoid Pharmacokinetics. Chemistry and Biodiversity, 2007, 4, 1770-1804.	1.0	833
2	Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 2014, 144, 12-41.	1.6	572
3	Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716. Archives of General Psychiatry, 2001, 58, 322.	13.8	437
4	Oral Fluid Testing for Drugs of Abuse. Clinical Chemistry, 2009, 55, 1910-1931.	1.5	340
5	Cannabis effects on driving lateral control with and without alcohol. Drug and Alcohol Dependence, 2015, 154, 25-37.	1.6	182
6	Identification of Recent Cannabis Use: Whole-Blood and Plasma Free and Glucuronidated Cannabinoid Pharmacokinetics following Controlled Smoked Cannabis Administration. Clinical Chemistry, 2011, 57, 1406-1414.	1.5	149
7	Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology, 2007, 194, 505-515.	1.5	144
8	Drug abuse's smallest victims: in utero drug exposure. Forensic Science International, 2002, 128, 20-30.	1.3	142
9	Free and Clucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. Clinical Chemistry, 2016, 62, 1579-1592.	1.5	139
10	Impact of Prolonged Cannabinoid Excretion in Chronic Daily Cannabis Smokers' Blood on Per Se Drugged Driving Laws. Clinical Chemistry, 2013, 59, 519-526.	1.5	127
11	Phase I and II Cannabinoid Disposition in Blood and Plasma of Occasional and Frequent Smokers Following Controlled Smoked Cannabis. Clinical Chemistry, 2014, 60, 631-643.	1.5	127
12	Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clinical Chemistry, 2015, 61, 850-869.	1.5	119
13	Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2015, 407, 883-897.	1.9	116
14	Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2003, 17, 1665-1670.	0.7	113
15	Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. Current Topics in Behavioral Neurosciences, 2016, 32, 93-117.	0.8	113
16	Detection Times of Marijuana Metabolites in Urine by Immunoassay and GC-MS. Journal of Analytical Toxicology, 1995, 19, 443-449.	1.7	110
17	Qualitative Confirmation of 9 Synthetic Cannabinoids and 20 Metabolites in Human Urine Using LC–MS/MS and Library Search. Analytical Chemistry, 2013, 85, 3730-3738.	3.2	108
18	Identifying Prenatal Cannabis Exposure and Effects of Concurrent Tobacco Exposure on Neonatal Growth. Clinical Chemistry, 2010, 56, 1442-1450.	1.5	106

#	Article	IF	CITATIONS
19	Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 2013, 405, 9437-9448.	1.9	106
20	Smoked Cannabis' Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers. Journal of Analytical Toxicology, 2015, 39, 251-261.	1.7	106
21	Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography–high resolution mass spectrometry and library matching. Journal of Chromatography A, 2015, 1397, 32-42.	1.8	103
22	Extended urinary Δ9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug and Alcohol Dependence, 2009, 105, 24-32.	1.6	99
23	Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 2014, 406, 1763-1780.	1.9	97
24	Cannabinoid concentrations in hair from documented cannabis users. Forensic Science International, 2007, 169, 129-136.	1.3	95
25	Do Δ ⁹ â€ŧetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. Addiction, 2009, 104, 2041-2048.	1.7	94
26	Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA. AAPS Journal, 2015, 17, 660-677.	2.2	94
27	Urinary Elimination of 11-Nor-9-Carboxy-Â9-tetrahydrocannnabinol in Cannabis Users During Continuously Monitored Abstinence. Journal of Analytical Toxicology, 2008, 32, 562-569.	1.7	92
28	Implications of Plasma Â9-Tetrahydrocannabinol, 11-Hydroxy-THC, and 11-nor-9-Carboxy-THC Concentrations in Chronic Cannabis Smokers. Journal of Analytical Toxicology, 2009, 33, 469-477.	1.7	92
29	Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography–tandem mass spectrometry. Journal of Chromatography A, 2014, 1327, 105-117.	1.8	92
30	Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2011, 401, 1273-1283.	1.9	91
31	Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metabolism Reviews, 2015, 47, 124-174.	1.5	91
32	Maternal smoking during pregnancy and infant stress response: Test of a prenatal programming hypothesis. Psychoneuroendocrinology, 2014, 48, 29-40.	1.3	88
33	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS ONE, 2018, 13, e0190768.	1.1	88
34	Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Â9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis. Journal of Analytical Toxicology, 2012, 36, 405-412.	1.7	84
35	Current knowledge on cannabinoids in oral fluid. Drug Testing and Analysis, 2014, 6, 88-111.	1.6	84
36	Linear pharmacokinetics of 3,4â€methylenedioxypyrovalerone (<scp>MDPV</scp>) and its metabolites in the rat: relationship to pharmacodynamic effects. Addiction Biology, 2016, 21, 339-347.	1.4	83

#	Article	IF	CITATIONS
37	Validated method for the simultaneous determination of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography–mass spectrometry with positive chemical ionization. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 798, 145-154.	1.2	80
38	Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Testing and Analysis, 2017, 9, 905-915.	1.6	80
39	Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. Drug and Alcohol Dependence, 2007, 87, 258-267.	1.6	78
40	Cannabis effects on driving longitudinal control with and without alcohol. Journal of Applied Toxicology, 2016, 36, 1418-1429.	1.4	77
41	Estimating the Time of Last Cannabis Use from Plasma Δ9-Tetrahydrocannabinol and 11-nor-9-Carboxy-Δ9-Tetrahydrocannabinol Concentrations. Clinical Chemistry, 2005, 51, 2289-2295.	1.5	76
42	First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry. AAPS Journal, 2013, 15, 1091-1098.	2.2	75
43	Clinical Sensitivity and Specificity of Meconium Fatty Acid Ethyl Ester, Ethyl Glucuronide, and Ethyl Sulfate for Detecting Maternal Drinking during Pregnancy. Clinical Chemistry, 2015, 61, 523-532.	1.5	75
44	Methamphetamine Disposition in Oral Fluid, Plasma, and Urine. Annals of the New York Academy of Sciences, 2007, 1098, 104-121.	1.8	73
45	Identification of Hydrocodone in Human Urine Following Controlled Codeine Administration. Journal of Analytical Toxicology, 2000, 24, 530-535.	1.7	70
46	A Study of peptide-peptide interaction by matrix-assisted laser desorption/ionization. Journal of the American Society for Mass Spectrometry, 2001, 12, 88-96.	1.2	70
47	Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug and Alcohol Dependence, 2016, 161, 298-306.	1.6	70
48	Oral Fluid Cannabinoids in Chronic, Daily Cannabis Smokers during Sustained, Monitored Abstinence. Clinical Chemistry, 2011, 57, 1127-1136.	1.5	69
49	Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry. AAPS Journal, 2016, 18, 1489-1499.	2.2	69
50	Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction, 2011, 106, 499-506.	1.7	68
51	Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1239-1246.	1.1	65
52	High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. Clinical Chemistry, 2016, 62, 157-169.	1.5	65
53	Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. Drug and Alcohol Dependence, 2017, 175, 67-76.	1.6	65
54	Cannabis in Sport. Sports Medicine, 2011, 41, 949-966.	3.1	64

#	Article	IF	CITATIONS
55	Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3′-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography–mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 814, 233-240.	1.2	60
56	Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. Drug Metabolism Reviews, 2016, 48, 237-265.	1.5	60
57	Development and validation of a solid-phase extraction gas chromatography–mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat. Analytical and Bioanalytical Chemistry, 2008, 392, 115-127.	1.9	58
58	A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Analytical and Bioanalytical Chemistry, 2009, 393, 1977-1990.	1.9	58
59	Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. American Journal on Addictions, 2014, 23, 234-242.	1.3	58
60	Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. Forensic Toxicology, 2015, 33, 295-310.	1.4	58
61	Metabolic profiling of new synthetic cannabinoids AMB and 5Fâ€AMB by human hepatocyte and liver microsome incubations and highâ€resolution mass spectrometry. Rapid Communications in Mass Spectrometry, 2016, 30, 1067-1078.	0.7	56
62	LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-β-D-glucuronide, morphine-6-β-D-glucuronide, and codeine-6-β-D-glucuronide in human urine. Journal of Mass Spectrometry, 2005, 40, 1412-1416.	0.7	55
63	Quantification of nicotine, cotinine, trans-3′-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 863, 107-114.	1.2	55
64	High-throughput simultaneous analysis of buprenorphine, methadone, cocaine, opiates, nicotine, and metabolites in oral fluid by liquid chromatography tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2010, 398, 915-924.	1.9	54
65	Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. Drug Testing and Analysis, 2014, 6, 728-738.	1.6	54
66	Intra- and Intersubject Whole Blood/Plasma Cannabinoid Ratios Determined by 2-Dimensional, Electron Impact GC-MS with Cryofocusing. Clinical Chemistry, 2009, 55, 1188-1195.	1.5	53
67	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB. Biological Psychiatry, 2016, 80, 691-701.	0.7	53
68	Excretion of Δ9-tetrahydrocannabinol in sweat. Forensic Science International, 2008, 174, 173-177.	1.3	52
69	Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy. Clinical Chemistry, 2016, 62, 367-377.	1.5	51
70	In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. AAPS Journal, 2016, 18, 455-464.	2.2	50
71	Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. Accident Analysis and Prevention, 2016, 92, 219-229.	3.0	49
72	Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. Analytical and Bioanalytical Chemistry, 2016, 408, 6461-6471.	1.9	49

#	Article	IF	CITATIONS
73	Maternal Methadone Dose, Placental Methadone Concentrations, and Neonatal Outcomes. Clinical Chemistry, 2011, 57, 449-458.	1.5	48
74	Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 2016, 1453, 34-42.	1.8	48
75	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. Clinical Chemistry, 2017, 63, 1008-1021.	1.5	48
76	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. Translational Psychiatry, 2020, 10, 71.	2.4	48
77	Oral Fluid Testing: Promises and Pitfalls. Clinical Chemistry, 2011, 57, 805-810.	1.5	47
78	Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. Analytical and Bioanalytical Chemistry, 2013, 405, 8451-8461.	1.9	47
79	Simultaneous analysis of buprenorphine, methadone, cocaine, opiates and nicotine metabolites in sweat by liquid chromatography tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2011, 400, 69-78.	1.9	46
80	Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. Forensic Science International, 2014, 241, 27-34.	1.3	46
81	4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicology, 2016, 34, 61-75.	1.4	46
82	In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis. Clinical Chemistry, 2013, 59, 1108-1117.	1.5	45
83	Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatographyâ€ŧandem mass spectrometry. Drug Testing and Analysis, 2015, 7, 684-694.	1.6	45
84	Cocaine and Metabolites Urinary Excretion after Controlled Smoked Administration*. Journal of Analytical Toxicology, 2007, 31, 462-468.	1.7	44
85	Simultaneous and sensitive measurement of nicotine, cotinine, trans-3′-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3537-3542.	1.2	44
86	<i>In vitro, in vivo</i> and <i>in silico</i> metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis, 2016, 8, 65-82.	0.6	44
87	Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. Clinical Chemistry, 2017, 63, 647-662.	1.5	44
88	Excretion of Methamphetamine and Amphetamine in Human Sweat Following Controlled Oral Methamphetamine Administration. Clinical Chemistry, 2008, 54, 172-180.	1.5	43
89	Disposition of Cannabinoids in Oral Fluid after Controlled Around-the-Clock Oral THC Administration. Clinical Chemistry, 2010, 56, 1261-1269.	1.5	43
90	Performance characteristics of the Cozart® RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration. Forensic Science International, 2004, 141, 41-48.	1.3	41

#	Article	IF	CITATIONS
91	Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug and Alcohol Dependence, 2012, 125, 313-319.	1.6	41
92	Estimating Time of Last Oral Ingestion of Cannabis From Plasma THC and THCCOOH Concentrations. Therapeutic Drug Monitoring, 2006, 28, 540-544.	1.0	40
93	3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography–high resolution mass spectrometry. Analytica Chimica Acta, 2014, 827, 54-63.	2.6	40
94	Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and <i>Ad libitum</i> Cannabis Smoking in Chronic Frequent Users. Journal of Analytical Toxicology, 2015, 39, 580-587.	1.7	40
95	Highâ€resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, <i>N</i> â€(adamantanâ€lâ€yl)â€lâ€(5â€fluoropentyl)â€l <i>H</i> â€indoleâ€3â€carboxamide (STSâ€l35), u human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Testing and Analysis, 2015, 7, 187-198.	sing cryop	reserved
96	Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-?-D-glucuronide and norbuprenorphine-3-?-D-glucuronide in human plasma. Journal of Mass Spectrometry, 2005, 40, 70-74.	0.7	39
97	A validated method for the determination of nicotine, cotinine,trans-3â€2-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. Journal of Mass Spectrometry, 2006, 41, 815-821.	0.7	39
98	Umbilical Cord Monitoring of In Utero Drug Exposure to Buprenorphine and Correlation with Maternal Dose and Neonatal Outcomes. Journal of Analytical Toxicology, 2010, 34, 498-505.	1.7	39
99	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Current Neuropharmacology, 2017, 15, 682-691.	1.4	39
100	Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 814, 369-373.	1.2	38
101	Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. Analytical and Bioanalytical Chemistry, 2010, 397, 603-611.	1.9	38
102	Simultaneous quantification of Δ9-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography–high resolution mass spectrometry. Journal of Chromatography A, 2013, 1297, 123-130.	1.8	38
103	Urinary Cannabinoid Disposition in Occasional and Frequent Smokers: Is THC-Glucuronide in Sequential Urine Samples a Marker of Recent Use in Frequent Smokers?. Clinical Chemistry, 2014, 60, 361-372.	1.5	38
104	A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. Journal of Pain Research, 2016, Volume 9, 587-598.	0.8	38
105	Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluidâ€blood cannabinoid relationships. Drug Testing and Analysis, 2016, 8, 690-701.	1.6	38
106	Development and validation of a disk solid phase extraction and gas chromatography–mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 450-458, Development and validation of a liquid chromatographya€ atmospheric pressure chemical	1.2	36
107	Development and validation of a liquid chromatographyae atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related (MDMA) analytes in human meconium. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences,	1.2	36
108	2008, 867, 194-204. Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers. PLoS ONE, 2014, 9, e113694.	1.1	36

#	Article	IF	CITATIONS
109	Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. Forensic Science International, 2014, 241, 87-90.	1.3	36
110	Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Analytical and Bioanalytical Chemistry, 2013, 405, 4679-4689.	1.9	35
111	Rapid quantitative chiral amphetamines liquid chromatography–tandem mass spectrometry: Method in plasma and oral fluid with a cost-effective chiral derivatizing reagent. Journal of Chromatography A, 2014, 1358, 68-74.	1.8	35
112	Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. Analytical and Bioanalytical Chemistry, 2014, 406, 4117-4128.	1.9	35
113	Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Testing and Analysis, 2015, 7, 483-493.	1.6	35
114	Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. Addiction, 2010, 105, 2151-2159.	1.7	34
115	First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 2016, 408, 4845-4856.	1.9	34
116	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. Drug and Alcohol Dependence, 2017, 180, 68-75.	1.6	34
117	Optimization and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of nicotine, cotinine, trans-3′-hydroxycotinine and norcotinine in human oral fluid. Analytical and Bioanalytical Chemistry, 2009, 395, 2349-2357.	1.9	33
118	Aroundâ€ŧheâ€clock oral THC effects on sleep in male chronic daily cannabis smokers. American Journal on Addictions, 2013, 22, 510-514.	1.3	33
119	Metabolic characterization of AHâ€7921, a synthetic opioid designer drug: <i>in vitro</i> metabolic stability assessment and metabolite identification, evaluation of <i>in silico</i> prediction, and <i>in vivo</i> confirmation. Drug Testing and Analysis, 2016, 8, 779-791.	1.6	33
120	Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. Drug Testing and Analysis, 2016, 8, 682-689.	1.6	33
121	School-Aged Outcomes following Prenatal Methamphetamine Exposure: 7.5-Year Follow-Up from the Infant Development, Environment, andÂLifestyle Study. Journal of Pediatrics, 2016, 170, 34-38.e1.	0.9	32
122	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicology, 2017, 35, 20-32.	1.4	31
123	Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry. Forensic Science International, 2009, 188, 144-151.	1.3	30
124	Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Testing and Analysis, 2014, 6, 1002-1010.	1.6	30
125	Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification. Analytical and Bioanalytical Chemistry, 2014, 406, 1945-1955.	1.9	30
126	Simultaneous quantification of nicotine, opioids, cocaine, and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2009, 393, 1957-1965.	1.9	29

#	Article	IF	CITATIONS
127	Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?. Drug and Alcohol Dependence, 2013, 130, 68-76.	1.6	29
128	Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. Drug Testing and Analysis, 2015, 7, 467-474.	1.6	29
129	Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration. Journal of Applied Toxicology, 2017, 37, 922-932.	1.4	29
130	Sensitive Gas Chromatography-Mass Spectrometry Method for Simultaneous Measurement of MDEA, MDMA, and Metabolites HMA, MDA, and HMMA in Human Urine. Clinical Chemistry, 2006, 52, 1728-1734.	1.5	28
131	A validated positive chemical ionization GC/MS method for the identification and quantification of amphetamine, opiates, cocaine, and metabolites in human postmortem brain. Journal of Mass Spectrometry, 2006, 41, 175-184.	0.7	28
132	Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3065-3071.	1.2	28
133	Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Clinical Chemistry and Laboratory Medicine, 2015, 53, 423-34.	1.4	28
134	Cannabinoids and metabolites in expectorated oral fluid after 8Âdays of controlled around-the-clock oral THC administration. Analytical and Bioanalytical Chemistry, 2011, 401, 599-607.	1.9	27
135	Longâ€ŧerm stability of cannabinoids in oral fluid after controlled cannabis administration. Drug Testing and Analysis, 2017, 9, 143-147.	1.6	27
136	Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. Neuropsychopharmacology, 2017, 42, 649-660.	2.8	27
137	Effect of hydrolysis on identifying prenatal cannabis exposure. Analytical and Bioanalytical Chemistry, 2010, 397, 2335-2347.	1.9	26
138	Simultaneous quantification of nicotine, cotinine, trans-3′-hydroxycotinine, norcotinine and mecamylamine in human urine by liquid chromatography–tandem mass spectrometry. Clinica Chimica Acta, 2012, 413, 978-984.	0.5	26
139	Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine. Analytical and Bioanalytical Chemistry, 2014, 406, 6213-6223.	1.9	25
140	In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. Analytical and Bioanalytical Chemistry, 2014, 406, 785-792.	1.9	25
141	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS Journal, 2017, 19, 568-577.	2.2	25
142	Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. Analytical and Bioanalytical Chemistry, 2013, 405, 7269-7279.	1.9	24
143	Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. Bioanalysis, 2015, 7, 2041-2056.	0.6	24
144	Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 13-20.	1.2	23

#	Article	IF	CITATIONS
145	Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. Forensic Science International, 2016, 260, 95-101.	1.3	23
146	Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography. Biological Psychiatry, 2018, 84, 715-721.	0.7	23
147	Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. Drug Testing and Analysis, 2015, 7, 114-120.	1.6	22
148	Optimization of recombinant βâ€glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. Drug Testing and Analysis, 2018, 10, 518-529.	1.6	22
149	Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. Analytical and Bioanalytical Chemistry, 2013, 405, 4067-4076.	1.9	21
150	3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. Analytical and Bioanalytical Chemistry, 2014, 406, 587-599.	1.9	21
151	Deterring driving under the influence of cannabis. Addiction, 2015, 110, 1697-1698.	1.7	21
152	Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. Forensic Toxicology, 2016, 34, 256-267.	1.4	21
153	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 27-35.	1.4	21
154	Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol. Journal of Studies on Alcohol and Drugs, 2018, 79, 441-446.	0.6	21
155	Sensitivity and Specificity of the Cozart Microplate EIA Cocaine Oral Fluid at Proposed Screening and Confirmation Cutoffs. Clinical Chemistry, 2003, 49, 1498-1503.	1.5	20
156	Modern analytical technologies for the detection of drug abuse and doping. Drug Discovery Today: Technologies, 2006, 3, 49-57.	4.0	20
157	11-Nor-9-carboxy-â^†9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography–tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2013, 405, 6019-6027.	1.9	20
158	Validation of an ELISA Synthetic Cannabinoids Urine Assay. Therapeutic Drug Monitoring, 2015, 37, 661-669.	1.0	20
159	Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing. Analytical and Bioanalytical Chemistry, 2015, 407, 4639-4648.	1.9	20
160	Development and validation of a liquid chromatography–tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine. Analytical and Bioanalytical Chemistry, 2008, 392, 903-911.	1.9	19
161	Methamphetamine and Amphetamine Isomer Concentrations in Human Urine Following Controlled Vicks VapoInhaler Administration. Journal of Analytical Toxicology, 2014, 38, 524-527.	1.7	19
162	Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography–tandem mass spectrometry. Journal of Chromatography A, 2016, 1446, 70-77.	1.8	19

#	Article	IF	CITATIONS
163	A validated gas chromatographic–electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 876, 266-276.	1.2	18
164	Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry. Analytical and Bioanalytical Chemistry, 2009, 394, 513-522.	1.9	18
165	Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. Drug and Alcohol Dependence, 2016, 163, 116-125.	1.6	18
166	CB1 – Cannabinoid Receptor Antagonist Effects on Cortisol in Cannabis-Dependent Men. American Journal of Drug and Alcohol Abuse, 2012, 38, 114-119.	1.1	17
167	Cannabis-Impaired Driving: A Public Health and Safety Concern. Clinical Chemistry, 2015, 61, 1223-1225.	1.5	17
168	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 543-550.	1.3	17
169	Correlation of creatinine―and specific gravityâ€normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. Drug Testing and Analysis, 2019, 11, 968-975.	1.6	17
170	Oral fluid with three modes of collection and plasma methamphetamine and amphetamine enantiomer concentrations after controlled intranasal lâ€nethamphetamine administration. Drug Testing and Analysis, 2015, 7, 877-883.	1.6	15
171	Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations. AJP Reports, 2016, 06, e385-e390.	0.4	15
172	Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol. Forensic Toxicology, 2015, 33, 260-278.	1.4	14
173	Oral fluid cannabinoids in chronic frequent cannabis smokers during <i>ad libitum</i> cannabis smoking. Drug Testing and Analysis, 2015, 7, 494-501.	1.6	14
174	Morphine and codeine in oral fluid after controlled poppy seed administration. Drug Testing and Analysis, 2015, 7, 586-591.	1.6	14
175	Cocaine and benzoylecgonine oral fluid onâ€site screening and confirmation. Drug Testing and Analysis, 2016, 8, 296-303.	1.6	13
176	In vitro stability of free and glucuronidated cannabinoids in blood and plasma collected in plastic gray-top sodium fluoride tubes following controlled smoked cannabis. Forensic Toxicology, 2016, 34, 179-185.	1.4	13
177	The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study. European Neuropsychopharmacology, 2017, 27, 679-690.	0.3	13
178	On-site oral fluid Δ9-tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration. Forensic Toxicology, 2017, 35, 133-145.	1.4	13
179	Simultaneous plasma and oral fluid morphine and codeine concentrations after controlled administration of poppy seeds with known opiate content. Forensic Toxicology, 2015, 33, 235-243.	1.4	12
180	Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. Journal of Analytical Toxicology, 2020, 44, 651-660.	1.7	12

#	Article	IF	CITATIONS
181	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. Clinical Chemistry, 2017, 63, 1753-1763.	1.5	11
182	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2018, 36, 304-312.	1.4	10
183	Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. Forensic Toxicology, 2015, 33, 202-212.	1.4	9
184	Pyrrolidinyl Synthetic Cathinones α-PHP and 4F-α-PVP Metabolite Profiling Using Human Hepatocyte Incubations. International Journal of Molecular Sciences, 2021, 22, 230.	1.8	9
185	Re: "Trends in Alcohol and Other Drugs Detected in Fatally Injured Drivers in the United States, 1999-2010". American Journal of Epidemiology, 2014, 180, 862-863.	1.6	7
186	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2017, 35, 252-262.	1.4	7
187	Tobacco Exposure and Conditional Weight-for-Length Gain by 2 Years of Age. Journal of Pediatric Psychology, 2017, 42, 679-688.	1.1	7
188	Mice Lacking Multidrug Resistance Protein 1a Show Altered Dopaminergic Responses to Methylenedioxymethamphetamine (MDMA) in Striatum. Neurotoxicity Research, 2010, 18, 200-209.	1.3	6
189	Antiretroviral Drugs in Meconium: Detection for Different GestationalÂPeriods of Exposure. Journal of Pediatrics, 2015, 167, 305-311.e3.	0.9	6
190	MDMA Impairs Response to Water Intake in Healthy Volunteers. Advances in Pharmacological Sciences, 2016, 2016, 1-11.	3.7	6
191	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 2016, 1451, 97-106.	1.8	6
192	Quantification of ethyl glucuronide, ethyl sulfate, nicotine, and its metabolites in human fetal liver and placenta. Forensic Toxicology, 2018, 36, 102-112.	1.4	6
193	Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder. Schizophrenia Research, 2014, 152, 315-316.	1.1	5
194	In Reply. Clinical Chemistry, 2014, 60, 1236-1237.	1.5	1
195	Physiological reactivity during object manipulation among cigarette-exposed infants at 9months of age. Neurotoxicology and Teratology, 2015, 48, 64-68.	1.2	1
196	Commentary. Clinical Chemistry, 2014, 60, 1484-1485.	1.5	0